Sobrevida a 5 años de pacientes sometidos a gastrectomía por adenocarcinoma gástrico en el Hospital Naval Almirante Nef entre 2010-2015 / 5-year survival of patients undergoing gastrectomy for gastric adenocarcinoma at Hospital Naval Almirante Nef between 2010-2015

Resumen Introducción: El cáncer gástrico es de los tumores malignos más comunes en el mundo y es de alta prevalencia en Chile. La tasa de mortalidad anual es de 26/100.000 habitantes para hombres y 12/100.000 para mujeres. La cirugía es el tratamiento con mayor probabilidad de curación, prolonga la sobrevida global y libre de enfermedad. La sobrevida global a 5 años reportada a nivel mundial es cercana al 30%. No contamos con datos en la región de Valparaíso sobre la sobrevida en pacientes con cáncer gástrico. Objetivo: Caracterizar a los pacientes operados por adenocarcinoma y estimar su sobrevida a 5 años. Materiales y Método: Realizamos un estudio retrospectivo a partir de la revisión de fichas clínicas de pacientes sometidos a gastrectomía por adenocarcinoma gástrico. La variable principal analizada fue la sobrevida a 5 años. Resultados: Se incluyeron 69 pacientes, el promedio de sobrevida fue de 31,7 (DE 25,3) meses y la sobrevida fue de 46% a 5 años. Encontramos diferencia al comparar grados de compromiso ganglionar según TNM (p = 0,0001). Según estadio se obtuvo un valor P cercano a la significancia estadística (p = 0,083). Otras variables sugieren diferencia en sobrevida sin lograr significancia estadística. Discusión: Presentamos resultados similares a estudios nacionales, posicionándonos con mejores resultados que países de occidente, pero aún muy por debajo de la sobrevida reportada en Japón (> 70%). Conclusión: Logramos caracterizar acabadamente a los pacientes operados por adenocarcinoma, su sobrevida a 5 años, además de apoyar la asociación entre distintos grados de compromiso ganglionar.

Introduction: Gastric cancer is one of the most common cancers worldwide. It is highly prevalent in Chile, with a mortality rate of 26/100,000 inhabitants for men and 12/100,000 for women. Surgical resection remains the treatment of choice, it aims to improve the quality of life and prolong overall survival and disease-free survival. The 5-year survival rate reported worldwide is close to 30%. We do not have data on survival rates in Valparaíso for patients with gastric cancer. Aim: To characterize patients with gastric adenocarcinoma that underwent gastric resection and determine their survival rate at 5 years post gastrectomy. Materials and Method: We performed a retrospective descriptive review of medical records of patients who underwent gastrectomy for gastric adenocarcinoma. The main variable analyzed was the 5-year survival rate. Results: 69 patients were included; the average survival was 31.7 (SD 25.3) months and the survival rate at 5 years was 46%. A difference was found when comparing degrees of lymph node involvement according to TNM (p = 0.0001). Depending on the stage, we obtained a P value close to being statistically significant (p = 0.083). Other variables suggested differences in survival rates without achieving statistical significance. Discussion: We obtained similar results to national studies. We obtained better survival rates than western countries, however our results are still lower than those from Japan (> 70%). Conclusions: We were able to finely characterize patients with gastric adenocarcinoma who underwent gastrectomy, their 5-year survival rate, and also to support association between different degrees of lymph node involvement and survival rates.

Conversion therapy for gastric cancer: expanding the treatment possibilities / Terapia de conversão no câncer gástrico: ampliando as possibilidades de tratamento

ABSTRACT Background: Conversion therapy in gastric cancer (GC) is defined as the use of chemotherapy/radiotherapy followed by surgical resection with curative intent of a tumor that was prior considered unresectable or oncologically incurable. Aim: To evaluate the results of conversion therapy in the treatment of GC. Methods: Retrospective analysis of all GC surgeries between 2009 and 2018. Patients who received any therapy before surgery were further identified to define the conversion group. Results: Out of 1003 surgeries performed for GC, 113 cases underwent neoadjuvant treatment and 16 (1.6%) were considered as conversion therapy. The main indication for treatment was: T4b lesions (n=10), lymph node metastasis (n=4), peritoneal carcinomatosis and hepatic metastasis in one case each. The diagnosis was made by imaging in 14 cases (75%) and during surgical procedure in four (25%). The most commonly used chemotherapy regimens were XP and mFLOX. Major surgical complications occurred in four cases (25%) and one (6.3%) died. After an average follow-up of 20 months, 11 patients (68.7%) had recurrence and nine (56.3%) died. Prolonged recurrence-free survival over 40 months occurred in two cases. Conclusion: Conversion therapy may offer the possibility of prolonged survival for a group of GC patients initially considered beyond therapeutic possibility.

RESUMO Racional : A terapia de conversão no câncer gástrico (CG) é definida como o uso de quimio/radioterapia seguida de ressecção cirúrgica com intenção curativa de um tumor que era considerado irressecável ou oncologicamente incurável. Objetivo : Avaliar os resultados da terapia de conversão no tratamento do CG. Métodos : Análise retrospectiva de todas as operações de CG entre 2009 e 2018. Os pacientes que receberam alguma terapia antes da operação foram também identificados para definir o grupo de conversão. Resultados : Entre 1003 operações realizadas para o CG, 113 foram submetidos ao tratamento neoadjuvante e 16 (1,6%) considerados como terapia de conversão. As principais indicações para o tratamento foram: lesões T4b (n=10), metástase linfonodal (n=4), carcinomatose peritoneal e metástase hepática em 1 caso cada. O diagnóstico foi feito por exame de imagem em 14 casos (75%) e durante o procedimento cirúrgico em 4 casos (25%). Os esquemas quimioterápicos mais utilizados foram XP e mFLOX. Complicações cirúrgicas maiores ocorreram em 4 casos (25%) e 1 (6,3%) foi a óbito. Após seguimento médio de 20 meses, 11 pacientes (68,7%) apresentaram recidiva e 9 (56,3%) morreram. Sobrevida livre de recidiva prolongada acima de 40 meses ocorreu em dois casos. Conclusão : A terapia de conversão pode oferecer possibilidade de sobrevida prolongada para um grupo de pacientes com CG considerados inicialmente fora das possibilidades terapêuticas.

Pancreaticoduodenectomy: impact of the technique on operative outcomes and surgical mortality / Duodenopancreatectomia: impacto da técnica nos resultados operatórios e mortalidade cirúrgica

ABSTRACT Background: Pancreaticoduodenectomy (PD) is a procedure associated with significant morbidity and mortality. Initially described as gastropancreaticoduodenectomy (GPD), the possibility of preservation of the gastric antrum and pylorus was described in the 1970s. Aim: To evaluate the mortality and operative variables of PD with or without pyloric preservation and to correlate them with the adopted technique and surgical indication. Method: Retrospective cohort on data analysis of medical records of individuals who underwent PD from 2012 through 2017. Demographic, anthropometric and operative variables were analyzed and correlated with the adopted technique (GPD vs. PD) and the surgical indication. Results: Of the 87 individuals evaluated, 38 (43.7%) underwent GPD and 49 (53.3%) were submitted to PD. The frequency of GPD (62.5%) was significantly higher among patients with pancreatic neoplasia (p=0.04). The hospital stay was significantly shorter among the individuals submitted to resection due to neoplasias of less aggressive behavior (p=0.04). Surgical mortality was 10.3%, with no difference between GPD and PD. Mortality was significantly higher among individuals undergoing resection for chronic pancreatitis (p=0.001). Conclusion: There were no differences in mortality, surgical time, bleeding or hospitalization time between GPD and PD. Pancreas head neoplasm was associated with a higher indication of GPD. Resection of less aggressive neoplasms was associated with lower morbidity and mortality.

RESUMO Racional : A duodenopancreatectomia (DP) é procedimento associado com significativa morbimortalidade. Inicialmente descrita como gastroduodenopancreatectomia (GDP), a possibilidade de preservação do antro gástrico e piloro foi descrita na década de 1970. Objetivo : Avaliar a mortalidade e variáveis operatórias da DP com ou sem preservação pilórica e correlacioná-las com a técnica adotada e indicação cirúrgica. Método: Estudo de coorte histórica, baseado em análise de dados de registros médicos de indivíduos submetidos à DP entre os anos de 2012 a 2017. Foram analisadas variáveis demográficas, antropométricas e operatórias e correlacionadas com a técnica adotada (GDP vs. DP) e a indicação cirúrgica. Resultados : Dos 87 indivíduos avaliados, 38 (43,7%) foram submetidos à GDP e 49 (53,3%) à DP. A frequência de realização da GDP (62,5%) foi significativamente maior entre os pacientes com neoplasia de pâncreas (p=0,04). O tempo de internação total foi significativamente menor entre os indivíduos submetidos à ressecção por neoplasias de comportamento menos agressivo (p=0,04). A mortalidade cirúrgica foi de 10,3%, não havendo diferença entre GDP e DP. A mortalidade foi significativamente maior entre os indivíduos submetidos à ressecção por pancreatite crônica (p=0,001). Conclusão : Não houve diferenças na morbimortalidade, tempo cirúrgico, sangramento ou tempo de internação entre GDP e DP. A neoplasia de cabeça de pâncreas associou-se mais com indicação de GDP. A ressecção de neoplasias menos agressivas associou-se a menor morbimortalidade.

Oncological outcomes in extended time intervals between preoperative chemoradiotherapy with capecitabine and surgery in operable rectal adenocarcinoma / Resultados oncológicos en intervalos extendidos de tiempo entre quimioradioterapia preoperatoria con capecitabina y cirugía en adenocarcinoma rectal operable

Objective: To assess whether extended time intervals (8-12, 13-20 and >20 weeks) between the end of neoadjuvant chemoradiotherapy and surgery affect overall survival, disease-free survival. Materials and methods: Retrospective study in 120 patients with rectal adenocarcinoma without evidence of metastasis (T1-4/N0-2/M0) at the time of diagnosis that underwent surgery with curative intent after neoadjuvant chemoradiotherapy with capecitabine and obtained R0 or R1 resection between January 2010 to December 2014 at the National Cancer Institute of Peru. Dates were evaluated by Kaplan-Meier method, log- rank test and Cox regression analysis. Results: Of the 120 patients, 70 were women (58%). The median age was 63(26-85) years. All received neoadjuvant chemoradiotherapy. No significant difference was found between the association of the median radial (0.6, 0.7 and 0.8 cm; p=0.826) and distal edge (3.0, 3.5 and 4.0 cm; p=0.606) with time interval groups and similarly the mean resected (18.8, 19.1 and 16.0; p=0.239) and infiltrated nodules (1.05, 1.29 and 0.41); p=0.585). The median follow-up time of overall survival and desease free survival was 40 and 37 months, respectively. No significant differences were observed in overall survival (79.0%, 74.6% and 71.1%; p=0.66) and disease-free survival (73.7%, 68.1% and 73.6%; p=0.922) according to the three groups studied at the 3-year of follow-up. Conclusions: We found that widening the time intervals between the end of neoadjuvant chemoradiotherapy and surgery at 24 weeks does not affect the overall survival, disease-free survival and pathological outcomes. It allows to extend the intervals of time for future studies that finally will define the best time interval for the surgery

Objetivo: Evaluar si los intervalos de tiempo extendidos (8-12, 13-20 y >20 semanas) entre el fin de la quimioradioterapia neoadyuvante y la cirugía afectan la sobrevida global, y la sobrevida libre de enfermedad. Material y métodos: Estudio retrospectivo de 120 pacientes con adenocarcinoma rectal sin evidencia de metástasis (T1-4/N0-2/M0) al momento del diagnóstico que se sometieron a cirugía con intención curativa luego de quimioradioterapia neoadyuvante con capecitabina y tuvieron resección R0 o R1 entre enero 2010 y diciembre 2014 en el Instituto Nacioanal de Enfermedades Neoplásicas de Perú. El análisis se hizo con el método de Kaplan-Meier, la prueba log-rank y la regresión de Cox. Resultados: De 120 pacientes, 70 fueron mujeres (58%). La mediana de la edad fue 63 años (26-85 años). Todos recibieron quimioradioterapia neoadyuvante. No hubo diferencia significativa entre la asociación de las medianas de los bordes radial (0,6, 0.7 y 0,8 cm; p=0,826) y distal (3,0, 3,5 y 4,0 cm; p=0,606) con los intervalos de tiempo de los grupos y similarmente con la media de los ganglios resecados (18,8, 19,1 y 16,0; p=0,239) e infiltrados (1,05, 1,29 y 0,41; p=0,585). No se observaron diferencias significativas en sobrevida global (79,0%, 74,6% y 71,1%; p=0,66) y sobrevida libre de enfermedad (73,7%, 68,1% y 73,6%; p=0,922), en los tres grupos estudiados a 3 años de seguimiento. Conclusiones: Encontramos que aumentar los intervalos de tiempo entre el fin de la quimioradioterapia neoadyuvante y la cirugía hasta 24 semanas no afecta la sobrevida global, sobrevida libre de enfermedad ni los desenlaces patológicos. Esto permitiría extender los intervalos de tiempo en estudios futuros para definir el mejor intervalo de tiempo para la cirugía

Surgical treatment of gastric cancer: a 10-year experience in a high-volume university hospital

OBJECTIVES: Surgery remains the cornerstone treatment modality for gastric cancer, the fifth most common type of tumor in Brazil. The aim of this study was to analyze the surgical treatment outcomes of patients with gastric cancer who were referred to a high-volume university hospital. METHODS: We reviewed all consecutive patients who underwent any surgical procedure due to gastric cancer from a prospectively collected database. Clinicopathological characteristics, surgical and survival outcomes were evaluated, with emphasis on patients treated with curative intent. RESULTS: From 2008 to 2017, 934 patients with gastric tumors underwent surgical procedures in our center. Gastric adenocarcinoma accounted for the majority of cases. Of the 875 patients with gastric adenocarcinoma, resection with curative intent was performed in 63.5%, and palliative treatment was performed in 22.4%. The postoperative surgical mortality rate for resected cases was 5.3% and was related to D1 lymphadenectomy and the presence of comorbidities. Analysis of patients treated with curative intent showed that resection extent, pT category, pN category and final pTNM stage were related to disease-free survival (DFS) and overall survival (OS). The DFS rates for D1 and D2 lymphadenectomy were similar, but D2 lymphadenectomy significantly improved the OS rate. Additionally, clinical factors and the presence of comorbidities had influence on the OS. CONCLUSIONS: TNM stage and the type of lymphadenectomy were independent factors related to prognosis. Early diagnosis should be sought to offer the optimal surgical approach in patients with less-advanced disease.

Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer

OBJECTIVE: The aim of this study was to determine the efficacy of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for the treatment of endometrial cancer. METHODS: Thirty-one patients with stage I-III endometrial cancer were recruited for this study. The stage I patients received only 252Californium neutron intracavitary brachytherapy with a two-channel applicator. The stage II and III patients received both 252Californium neutron intracavitary brachytherapy using a two-channel applicator and parallel-opposed whole pelvic radiotherapy. RESULTS: The five-year local control rate was 80.6% (25/31), the overall survival rate was 51.6% (16/31), and the disease-free survival rate was 54.8% (17/31). The incidence of serious late complications was 12.9% (4/31). CONCLUSIONS: 252Californium neutron intracavitary brachytherapy using a two-channel applicator combined with external beam radiotherapy was effective for treating endometrial cancer and the incidence of serious late complications related to this combination was within an acceptable range.

Transanal endoscopic operation for rectal cancer after neoadjuvant therapy

PURPOSE: In this paper we report the oncological outcomes from clinical series of patients with rectal cancer submitted to local excision after neoadjuvant therapy and discuss the indications for local excision in partial clinical responders. METHODS: We analysed a prospective database of 39 patients submitted to a transanal endoscopic operation for rectal cancer after neoadjuvant chemoradiation between 2006 and 2015, comparing clinical and pathological variables, perioperative complications, recurrence rate and overall survival. RESULTS: We obtained 15.4% ypT0, 17.9% ypT1, 35.9% ypT2 and 28.2% ypT3. After a median follow-up of 24 months, tumoral recurrence was observed in 4 patients, one of them with isolated pulmonary metastasis. R0 resection was achieved in 79.5%, and postoperative complications were observed in 30.2% patients and no perioperative mortality occur. Compromise surgical margins do not affect recurrence rate, and 94.9% of patients are alive nowadays. CONCLUSION: Local excision could be associated with low recurrence rate and good overall survival. Short hospitalization time and low level of serious complications observed could be an interesting option for patients who would not tolerate a radical procedure or for those who declined a total mesorectal excision. A strict long-term follow-up must be warranted to detect early tumoral recurrence.

Most small bowel cancers are revealed by a complication / A maioria dos cânceres de intestino delgado são revelados por uma complicação

ABSTRACT Objective To characterize the pattern of primary small bowel cancers in a tertiary East-European hospital. Methods A retrospective study of patients with small bowel cancers admitted to a tertiary emergency center, over the past 15 years. Results There were 57 patients with small bowel cancer, representing 0.039% of admissions and 0.059% of laparotomies. There were 37 (64.9%) men, mean age of 58 years; and 72 years for females. Out of 57 patients, 48 (84.2%) were admitted due to an emergency situation: obstruction in 21 (38.9%), perforation in 17 (31.5%), upper gastrointestinal bleeding in 8 (14.8%), and lower gastrointestinal bleeding in 2 (3.7%). There were 10 (17.5%) duodenal tumors, 21 (36.8%) jejunal tumors and 26 (45.6%) ileal tumors. The most frequent neoplasms were gastrointestinal stromal tumor in 24 patients (42.1%), adenocarcinoma in 19 (33.3%), lymphoma in 8 (14%), and carcinoids in 2 (3.5%). The prevalence of duodenal adenocarcinoma was 14.55 times greater than that of the small bowel, and the prevalence of duodenal stromal tumors was 1.818 time greater than that of the small bowel. Obstruction was the complication in adenocarcinoma in 57.9% of cases, and perforation was the major local complication (47.8%) in stromal tumors. Conclusion Primary small bowel cancers are usually diagnosed at advanced stages, and revealed by a local complication of the tumor. Their surgical management in emergency setting is associated to significant morbidity and mortality rates.

RESUMO Objetivo Caracterizar o padrão de neoplasias malignas primárias do intestino delgado em um hospital terciário de Leste Europeu. Métodos Estudo retrospectivo de pacientes com câncer de intestino delgado, internados em um hospital terciário e de emergência, ao longo dos últimos 15 anos. Resultados Foram avaliados 57 pacientes com neoplasias malignas gastrintestinais, o que representou 0,039% das admissões e 0,059% das laparotomias realizadas. Total de 37 (64,9%) pacientes masculinos, média de idade de 58 anos, e de 72 anos para mulheres. Dentre os 57 pacientes, 48 (84,2%) foram internados em situação de emergência: obstrução intestinal em 21 (38,9%), perfuração em 17 (31,5%), hemorragia digestiva alta em 8 (14,8%), e hemorragia digestiva baixa em 2 (3,7%). Houve 10 (17,5%) tumores duodenais, 21 (36,8%) jejunais e 26 (45,6%) ileais. As neoplasias mais frequentes foram tumor estromal gastrintestinal, em 24 (42,1%) pacientes, adenocarcinoma em 19 (33,3%), linfoma em 8 (14%) e carcinoides em 2 (3,5%). A prevalência de adenocarcinoma duodenal foi 14,55 vezes maior do que a do intestino delgado, e a prevalência de tumores estromais duodenais foi 1,818 vez maior do que a do intestino delgado. A obstrução intestinal foi complicação do adenocarcinoma em 57,9% dos casos, e a perfuração foi a principal complicação local (47,8%) dos tumores estromais. Conclusão As neoplasias malignas primárias do intestino delgado foram geralmente diagnosticadas em estado avançado e reveladas por uma complicação local do tumor. O tratamento cirúrgico em situação de emergência está associado à significativa morbimortalidade.

Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered / Maior sobrevida global em pacientes com câncer pancreático metastático: o impacto de onde e como o tratamento é realizado

Objective To determine the overall survival of patients with advanced pancreatic cancer and evaluate factors that impact prognosis in a private cancer center.Methods Data from the Hospital Cancer Registry at Hospital Israelita Albert Einstein were retrospectively collected. The patients enrolled had metastatic cancer at diagnosis or earlier staging and subsequent recurrence. Cases of neuroendocrine tumors were excluded.Results A total of 65 patients were evaluated, including 63 with adenocarcinoma. The median overall survival for patients in all stages was 20.7 months (95%CI: 15.6-25.7), while the overall survival of metastatic disease was 13.3 months. Among the 33 cases with stage IV cancer, there was no evidence of a statistically significant association between median survival and CA19-9 dosage (p=0.212), tumor location (p=0.482), first treatment performed (p=0.337), lymphovascular invasion (p=0.286), and age (p=0.152). However, the number of lines of chemotherapy was significantly associated with survival (log-rank p=0.013), with an estimated median survival of 10.2 months for patients who received up to two lines of treatment and 23.5 months for those receiving more than two lines of chemotherapy.Conclusion The survival of patients treated was longer than that reported in the literature. The only statistically significant factor related to increased survival was higher number of lines of chemotherapy received. We believe that the higher socioeconomic status of patients surveyed in this study, as well as their greater access to treatment options, may have influenced their overall survival.

Objetivo Determinar a sobrevida global dos pacientes com câncer pancreático avançado e avaliar fatores com impacto prognóstico em um centro de câncer privado.Métodos Foram coletados retrospectivamente os dados do Registro de Câncer do Hospital Israelita Albert Einstein. Os pacientes incluídos apresentaram câncer metastático ao diagnóstico ou em estádio mais precoce com recorrência subsequente. Os casos de tumores neuroendócrinos foram excluídos.Resultados Foram avaliados 65 pacientes, incluindo 63 com adenocarcinoma. A sobrevida global mediana dos pacientes em todos os estádios foi 20,7 meses (IC95%: 15,6-25,7), enquanto a sobrevida global de doença metastática foi de 13,3 meses. Entre os 33 casos com câncer em estádio IV, não houve evidência de associação estatisticamente significativa entre a sobrevida mediana e CA19-9 ao diagnóstico (p=0,212), localização do tumor (p=0,482), primeiro tratamento realizado (p=0,337), invasão vasculo-linfática (p=0,286) e idade (p=0,152). No entanto, o número de linhas de quimioterapia foi significativamente associado com a sobrevida (log-rankp=0,013), com uma sobrevida mediana estimada de 10,2 meses para os pacientes que receberam até duas linhas de tratamento e de 23,5 meses para os que receberam mais de duas linhas.Conclusão A sobrevida dos pacientes tratados foi maior do que o relatado na literatura. O único fator estatisticamente significativo relacionado à maior sobrevida foi maior número de linhas de quimioterapia recebidas. Acreditamos que o nível socioeconômico dos pacientes pesquisados neste estudo, assim como seu maior acesso a opções de tratamento, pode ter influenciado em sua sobrevivência global.

The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011 / O impacto do uso do erlotinibe em pacientes portadores de neoplasia de pulmão de não pequenas células tratados em um hospital geral de referência e clínica particular de oncologia no período de 2005 a 2011

ABSTRACT Objective: To report the demographic data and clinical outcomes of non-small-cell lung cancer patients exposed to erlotinib in any line of treatment. Methods: This was a retrospective cohort study of nonsmall-cell lung cancer patients from a reference general hospital and a private oncology clinic, who received erlotinib from 2005 to 2011. Statistical analysis was performed and we evaluated demographic data and response to treatment, by correlating the results of this first cohort published in Brazil with results of current literature. Results: A total of 44 patients were included; 65.9% were diagnosed with adenocarcinoma, and 63.6% had metastatic disease. The mean age was 63.3 years. The median follow-up was 47.9 months. Epidermal growth factor receptor mutation screening was performed in 22.7% of patients (n=10), with mutation present in 30% of patients. The median overall survival was 46.3 months, and there was a higher probability of survival at 60 months for females compared to males (29.4% versus 15.8%; p=0.042). The other variables did not present significant statistical difference. Conclusion: We collected the largest cohort of patients with non-small-cell lung cancer who have used erlotinib in Brazil to date, and demonstrated that outcomes of patients treated at our clinic during the study period were consistent with the results of current literature in similar patients. .

RESUMO Objetivo: Relatar as características demográficas e a evolução de pacientes com neoplasia de pulmão de não pequenas células que receberam erlotinibe em qualquer linha de tratamento. Métodos: Coletamos retrospectivamente dados de pacientes portadores de neoplasia de pulmão de não pequenas células que receberam erlotinibe em qualquer linha de tratamento em um hospital geral de referência e em uma clínica particular de oncologia em São Paulo, no período de 2005 a 2011. Foi realizada a análise estatística e foram avaliados aspectos demográficos e resposta ao tratamento estabelecido, correlacionando os resultados dessa primeira coorte publicada no Brasil com resultados da literatura vigente. Resultados: Foram avaliados 44 pacientes, dos quais 65,9% eram portadores de adenocarcinoma e 63,6% tinham doença metastática. A média de idade foi de 63,3 anos. O seguimento mediano foi de 47,9 meses. A pesquisa de mutação do receptor do fator de crescimento epidérmico foi realizada em 22,7% dos pacientes (n=10), resultando positiva em 30% dos avaliados. A sobrevida global mediana foi de 46,3 meses, e observou-se uma probabilidade maior de sobrevida em 60 meses para o grupo feminino, quando comparado ao grupo masculino (29,4% versus 15,8%; p=0,042). As demais variáveis não apresentaram diferença estatística significativa. Conclusão: Coletamos a maior sequência de pacientes com neoplasia de pulmão de não pequenas células que fizeram uso de erlotinibe no Brasil até a data vigente e demonstramos que a evolução dos pacientes tratados no período avaliado teve resultados concordantes com os da literatura vigente em pacientes semelhantes. .

Gastrectomía totalmente laparoscópica por neoplasias gástricas: Experiencia en un centro público / Totally laparoscopic gastrectomy for the treatment of gastric tumors

Background: The laparoscopic approach for the treatment of gastric tumors has many advantages. Aim: To evaluate the results of a laparoscopic gastrectomy program developed in a public hospital. Patients and Methods: Retrospective review of epidemiological, perioperative and follow-up data of patients who were treated with a laparoscopic gastrectomy due to gastric tumors between 2006 and 2013. A totally laparoscopic technique was used for all cases. Complications were evaluated according to the Clavien-Dindo classification. Results: Fifty one patients, aged 65 (36-85) years, underwent a laparoscopic gastrectomy. In 22 patients a total gastrectomy was performed. Conversion rate to open surgery was 8%. Operative time was 330 (90-500) min and bleeding was 200 (20-500) ml. Median hospital stay was 7 (3-37) days. Postoperative morbidity was present in 17 (33%) patients, 3 (6%) patients had complications grade 3 or higher and one patient died (1.9%). Tumor pathology was adenocarcinoma in 39 patients. A complete resection was achieved in 97%. Twenty nine patients (74%) with gastric adenocarcinoma had early gastric cancer and 84% of patients were in stage one. Median lymph node count was 24. Median follow-up was 26 (1-91) months. There was no cancer related mortality among patients subjected to a curative resection. Overall survival for patients with adenocarcinoma was 92% at 3 years. Conclusions: This study supports the feasibility and safety of a laparoscopic gastrectomy program in a public hospital; with low morbidity, adequate lymph node dissection and long-term survival. This approach must be considered an option for selected patients with gastric cancer.

Evaluation of nrratio in selecting patients foradjuvant chemoradiotherapy afteer d2-gastrectomy / Avaliacao do N-Ratio para a selecao de pacientes candidatos a quimioradioterapia adjuvante apos gastrectomia D2

Context Whether adjuvant chemoradiotherapy may contribute to improve survival outcomes after D2-gastrectomy remains controvertial. Objective To explore the clinical utility of N-Ratio in selecting gastric cancer patients for adjuvant chemoradiotherapy after D2-gastrectomy. Methods A retrospective cohort study was carried out on gastric cancer patients who underwent D2-gastrectomy alone or D2-gastrectomy plus adjuvant chemoradiotherapy (INT-0116 protocol) at the Hospital A. C. Camargo from September 1998 to December 2008. Statistical analysis were performed using multiple conventional methods, such as c-statistic, adjusted Cox's regression and stratified survival analysis. Results Our analysis involved 128 patients. According to c-statistic, the N-Ratio (i.e., as a continuous variable) presented “area under ROC curve” (AUC) of 0.713, while the number of metastatic nodes presented AUC of 0.705. After categorization, the cut-offs provide by Marchet et al. displayed the highest discriminating power – AUC value of 0.702. This N-Ratio categorization was confirmed as an independent predictor of survival using multivariate analyses. There also was a trend of better survival by adding of adjuvant chemoradiotherapy only for patients with milder degrees of lymphatic spread – 5-year survival of 23.1% vs 66.9%, respectively (HR = 0.426, 95% CI 0.150–1.202; P = 0.092). Conclusions This study confirms the N-Ratio as a tool to improve the lymph node metastasis staging in gastric cancer and suggests the cut-offs provided by Marchet et al. as the best way for its categorization after a D2-gastrectomy. In these settings, the N-Ratio appears a useful tool to select patients for adjuvant chemoradiotherapy, and the benefit of adding this type of adjuvancy to D2-gastrectomy is suggested to be limited to patients with milder degrees of lymphatic spread (i.e., NR2, 10%–25%). .

Contexto A utilização de quimiorradioterapia adjuvante permanece controversa após a realização de gastrectomia D2. Objetivo Explorar a utilidade clínica do N-Ratio para a seleção de pacientes com câncer gástrico candidatos à quimiorradioterapia adjuvante após gastrectomia D2. Métodos Realizou-se estudo de coorte retrospectivo incluindo pacientes com câncer gástrico submetidos a gastrectomia D2, isoladamente ou associada à quimiorradioterapia adjuvante (protocolo INT-0116), no Hospital A.C. Camargo, de setembro de 1998 a dezembro de 2008. As análises estatísticas foram realizadas utilizando-se diversos métodos, tais como análise de área sob curvas ROC, regressão de Cox's ajustada e análise estratificada da sobrevivência. Resultados A análise envolveu 128 pacientes. Por análise das áreas sob curvas ROC, o N-Ratio apresentou AUC de 0,713 como variável contínua, enquanto o número total de linfonodos metastáticos apresentou AUC de 0,705. Na análise categorizada, os pontos-de-corte propostos por Marchet et al. apresentaram o maior poder de discriminação, com valor de AUC de 0,702. A categorização N-Ratio segundo estes autores foi confirmada como um preditor independente de sobrevivência, utilizando-se análises multivariadas. Observou-se tendência de melhor sobrevivência acrescentando-se quimiorradioterapia adjuvante apenas para pacientes com moderado grau de disseminação linfática (NR2, 10%-25%), entre os quais a sobrevivência em 5 anos foi de 23,1% vs 66,9%, respectivamente (HR = 0,426, IC 95% 0,150-1,202, P = 0,092). Conclusões Este estudo confirma o N-Ratio como uma medida para melhorar o estadiamento linfonodal no câncer gástrico e sugere que os pontos-de-corte descritos por Marchet et al. sejam a ...

Resultados del tratamiento con neoadyuvancia del cáncer de recto localmente avanzado / Preoperative chemoradiotherapy in rectal cancer, experience in 76 patients

Background: Preoperative chemoradiotherapy is helpful as an adjuvant treatment for locally advanced rectal carcinoma. Aim: To report the results of a prospective series of patients with rectal carcinoma treated with chemoradiotherapy and surgical excision. Material and Methods: Seventy six patients aged 28 to 84 years (51 percent women), with locally advanced rectal cancer (T3-T4 or N+) subjected to curative surgery and treated with radiotherapy and 5 fluoruracil with leucovorin, were included in this series. Results: Mean hospital stay was 12.5 +/- 7.2 days, 37 percent had operative complications and no patient died. The downstaging effect was more marked for local invasion than for lymph node involvement. In 21 percent of cases, a complete pathological response was achieved and no patient has had a relapse during a 59 months follow up. Conclusions: Among patients with rectal cancer, preoperative chemoradiotherapy does not increase surgical complications and has a marked impact in tumor downstaging.

Antecedentes: El tratamiento del cáncer de recto bajo localmente avanzado ha cambiado en la última década hacia la neoadyuvancia con radio quimioterapia (RQT) preoperatoria. Objetivo: Dar a conocer los resultados de una serie prospectiva de casos tratados con RQT preoperatoria más cirugía radical con resección total del mesorrecto. Pacientes y Método: se incluye los pacientes con un cáncer de recto medio e inferior localmente avanzado (T3-T4 y/o N+) tratados con intención curativa con radioterapia más 5-FU con leucovorina. Se detalla el impacto de la RQT en la pieza operatoria comparado con una serie similar sin radioterapia previa. Resultados: Se trata de 76 pacientes (51,3 por ciento mujeres) con un promedio etario de 61,9 años (extremos 28-84). El tiempo de hospitalización promedio fue 12,55 días (DE: 7,19; extremos 4-35), la morbilidad global de la serie fue 37 por ciento, no hubo mortalidad operatoria. El efecto del downstaging fue más marcado en el factor T que en el compromiso linfonodal y en el 21 por ciento de los casos se logró una respuesta patológica completa (RPC) o casi completa (RP), sin recidiva en este subgrupo luego de un seguimiento promedio de 59 meses. Conclusión: En esta serie la RQT preoperatoria no aumenta la morbilidad perioperatoria, tiene un impacto marcado en el downstaging patológico y la RPC o RP casi completa se asocia positivamente con la sobrevida a largo plazo.

Resultados del tratamiento quirúrgico del cáncer de colon: análisis de 439 pacientes / Surgical treatment of colon cancer: retrospective analysis of 439 patients

Background: Mortality for colon cancer duplicated in the last 15 years in Chile. Aim: To analyze immediate and late results of surgical treatment of colon cancer. Material and Methods: Retrospective analysis of 439 patients aged 22 to 92 years, 55 percent women, subjected to elective surgery for colon cancer between 1991 and 2007. Results: At the moment of surgery 86 percent of tumors were resectable and 25 percent were in stage IV Twenty one percent of patients had surgical complications, 4 percent had to be reoperated and 1 percent died. Ten years global survival for stages I to III was 82 percent. Survival significantly decreased for stages Illb and forward. Preoperative carcinoembrionic antigen, vascular permeation, the number of involved lymph nodes and chemotherapy were relevant prognostic factors. If TNM classification is included in the model, only vascular permeation and lymph node involvement remain as prognostic factors. Conclusions: TNM classification and lymph node involvement are the main survival prognostic factors in this series of patients with colon cancer.

Antecedentes: La mortalidad por cáncer de colon (CC) se ha duplicado en Chile en los últimos 15 años. El objetivo es analizar los resultados inmediatos y alejados del tratamiento quirúrgico del CC en un hospital público docente. Pacientes y Método: Se incluyen todos los pacientes intervenidos en forma electiva por un CC entre 1991 y 2007. Los pacientes fueron etapificados según el TNM 2002. Los pacientes estadios I a III con R0 son considerados como cirugía con intención curativa. Las curvas de sobrevida fueron estimadas según el método de Kaplan-Meier, las que se comparan con el test log-rank. Para determinar los factores pronósticos más relevantes en el análisis multivariado se utilizó el modelo de regresión de Cox. Resultados: Se trata de 439 pacientes, 55 por ciento mujeres, con una edad promedio de 67 años (extremos 22-92). La resecabilidad fue de 86 por ciento, el 25 por ciento de los casos estaba en estadio IV, la morbilidad fue 21 por ciento, la tasa de reoperaciones fue 4 por ciento y la mortalidad 1 por ciento. La sobrevida global de los estadios I a III fue 82 por ciento a 10 años, con una clara inflexión negativa de las curvas a partir del estadio IIIB. El CEA preoperatorio, la permeación vascular, el número de ganglios positivos y la quimioterapia aparecen como factores pronósticos relevantes. Al introducir el TNM en el modelo, la permeación vascular y el índice ganglionar conservan la significancia estadística. Conclusión: La cirugía resectiva del CC puede efectuarse con bajos índices de mortalidad. El índice ganglionar junto al TNM puede ser un factor pronóstico relevante en la toma de decisiones terapéuticas sobre adyuvancia en los pacientes en estadio III.

Resultados del tratamiento quirúrgico del cáncer del tercio superior del recto y de colon sigmoides: análisis comparativo / Comparative results of the surgical treatment of tumors located in the upper third of the rectum and sigmoid colon

Background: Tumors located in the upper third of the rectum can be treated in the same way as sigmoid tumors. This means that mesorrectum excision and neoadjuvant therapies are not necessary. Aim: To compare the results in terms of relapse and survival of elective surgery for sigmoid and upper third rectal tumors. Material and Methods: Retrospective analysis of patients operated for an upper third rectal or sigmoid cancer that were prospectively included in a database and had a minimum follow up of 18 months. Clinical and pathological variables and staging using TNM classification were considered as covariates in the analysis. Results: Fifty patients with a tumor of the upper third of the rectum, aged 30 to 84 years (24 females), with a follow up ranging from 12 to 206 months, and 107 patients with a sigmoid tumor, aged 22 to 91 years (62 females), with a follow up ranging from 13 to 204 months, were analyzed. Seven patients with rectal tumors (14 percent) and 12 patients with sigmoid tumors (11 percent), died during follow up (p = NS). Ten years actuarial overall survival was 85 percent for both groups. Conclusions: No differences in survival or relapse were observed in this group of patients with tumors located in the upper third of the rectum or sigmoid colon. Therefore both types of tumors can be treated in the same way.

Introducción: Se ha sugerido que los pacientes con un tumor del tercio superior del recto (RS) podrían tratarse en forma similar que los portadores de un cáncer de sigmoides (CS). Ello implica no realizar la resección total del mesorrecto ni someterlos a terapias neoadyuvantes. El objetivo de este estudio es comparar los resultados del tratamiento quirúrgico electivo de ambos tumores respecto de la recidiva y la sobrevida global. Pacientes y Método: Análisis retrospectivo de las características demográficas de los pacientes intervenidos por un adenocarcinoma de recto superior y de colon sigmoides con intención curativa en forma electiva en forma consecutiva con un seguimiento mínimo de 18 meses. Se considera variables clínicas (edad, género, enfermedades asociadas, antígeno carcinoembrionario (CEA) preoperatorio), histopatológicas (diferenciación y tamaño tumoral, número de ganglios examinados) y la estadificación de ambos grupos según TNM. Resultados: Se compara 50 pacientes portadores de un adenocarcinoma de RS en los estadios I a III con 107 pacientes intervenidos en el mismo período por un cáncer de CS con intención curativa. El seguimiento promedio de los pacientes con un tumor de RS fue de 88,62 meses (extremos 12-206), y de 71,67 meses en los casos de CS (extremos 13-204) (p = 0,05). Durante este período fallecen por la enfermedad 7 pacientes (14 por ciento) del grupo RS, 1 por recidiva locorregional y 6 por recidiva a distancia, con un rango entre 12 y 78 meses. En el grupo CS fallecen 12 pacientes (11,2 por ciento), 3 (2,8 por ciento) con recidiva locorregional y 9 con recidiva a distancia, entre 24 y 82 meses de seguimiento (p = 0,24). La sobrevida actuarial global a 10 años para ambos grupos fue de 85 por ciento. Conclusión: En este estudio no existen diferencias en cuanto a la recidiva global, la recidiva local ni la recidiva a distancia entre ambos grupos, lo que avala la estrategia de tratar en forma similar los tumores...

Quimiorradioterapia adyuvante en el cáncer gástrico resecado con intención curativa: análisis de supervivencia y toxicidad de pacientes tratados entre 1995 y 2003 en el Instituto Nacional del Cáncer, Chile / Results of adjuvant chemoradiation after curative surgery for gastric cancer: a retrospective study

Background: Survival rates after curative surgery for gastric cancer are disappointing. Therefore adjuvant therapeutic strategies are required. Aim: To analyze survival and side effects of treatment among gastric cancer patients treated with adjuvant chemo radiotherapy after curative resection of gastric adenocarcinoma. Material and methods: Retrospective review of medical records of 74 patients aged 20 to 74 years, treated with complete resection of gastric adenocarcinoma followed by adjuvant chemo radiation. Survival analysis was based on the records and information from the National Mortality Registry. Results: Five years survival fluctuated from 50 percent among patients in stage IB to 25 percent among those is stage IV. Significant acute toxicity was observed in 23 patients (31 percent). No patients died due to acute toxicity. Eleven patients (16.4 percent) developed significant late toxicity, with two possible deaths related to treatment. Conclusions: Postoperative chemo radiotherapy is feasible in our experience. Continues infusion of 5-fluoruracil is recommended to reduce toxicity.

Câncer de pulmão: histologia, estádio, tratamento e sobrevida / Lung cancer: histology, staging, treatment and survival

OBJETIVO: Analisar os principais tipos histológicos, estádio, tratamento e sobrevida dos portadores de câncer de pulmão. MÉTODOS: Estudo retrospectivo a partir da análise dos prontuários de pacientes acompanhados no Hospital das Clínicas da Faculdade de Medicina de Botucatu, num período de seis anos. RESULTADOS: De janeiro de 2000 a janeiro de 2006, foram acompanhados 240 doentes com câncer de pulmão, com predominância do sexo masculino (64 por cento). O tipo histológico mais freqüente foi o carcinoma escamoso (37,5 por cento), seguido pelo adenocarcinoma (30 por cento), carcinoma neuroendócrino (19,6 por cento) e carcinoma de grandes células (6,6 por cento). Apenas 131 pacientes (54,6 por cento) foram tratados. Destes, 52 pacientes (39,7 por cento) foram submetidos à quimioterapia exclusiva, 32 (24,4 por cento) realizaram quimioterapia associada à radioterapia e 47 (35,9 por cento) foram submetidos à cirurgia associada ou não à quimioterapia exclusiva e/ou radioterapia. Somente 27 pacientes (20,6 por cento) foram submetidos à cirurgia exclusiva.Em relação ao estadiamento, 34,4 por cento apresentavam, no momento do diagnóstico, estádio IV, 20,6 por cento estádio IIIB, 16,8 por cento estádio IIIA e os outros 28,2 por cento pertenciam aos estádios I e II. A sobrevida em cinco anos foi de 65 por cento para o estádio I e 25 por cento para os estádios remanescentes. CONCLUSÕES: O tipo histológico predominante foi o carcinoma escamoso e o de menor freqüência foi o carcinoma de grandes células. A maioria se encontrava em estádio avançado ao diagnóstico, estando nos estádios iniciais menos de 30 por cento dos casos. Isto justifica a baixa sobrevida e a pequena quantidade de pacientes submetidos ao tratamento cirúrgico exclusivo, em comparação à maioria que foi submetida à quimioterapia exclusiva.

OBJECTIVE: To analyze principal histological types of lung cancer, as well as the staging, treatment and survival of lung cancer patients. METHODS: This was a retrospective study based on the analysis of medical charts of patients treated at the Botucatu School of Medicine Hospital das Clínicas over a six-year period. RESULTS: From January of 2000 to January of 2006, 240 patients with lung cancer, most (64 percent) of whom were male, were treated. The most common histological type was squamous cell carcinoma (37.5 percent), followed by adenocarcinoma (30 percent), neuroendocrine carcinoma (19.6 percent) and large cell carcinoma (6.6 percent). Only 131 patients (54.6 percent) were treated. Of those, 52 patients (39.7 percent) received only chemotherapy, 32 (24.4 percent) were treated with chemotherapy combined with radiotherapy, and 47 (35.9 percent) were submitted to surgery alone or surgery accompanied by chemotherapy, with or without radiotherapy. Only 27 patients (20.6 percent) were submitted to surgery alone. Concerning staging, 34.4 percent presented stage IV at the time of diagnosis, 20.6 percent presented stage IIIB, 16.8 percent presented stage IIIA, and the remaining 28.2 percent were classified as stage I or II. Five-year survival was 65 percent for those in stage I and 25 percent for those in the remaining stages. CONCLUSIONS: Of the various histological types, the most common was squamous cell carcinoma and the least common was large cell carcinoma. Most cases presented advanced stages at the moment of diagnosis, and less than 30 percent of the cases presented early stages. This accounts for the low survival rate and the small number of patients submitted to surgical treatment alone, the majority being submitted to chemotherapy alone.

A exenteração pélvica no tratamento do câncer de reto estádio T4: experiência de 15 casos operados / Pelvic exenteration for T4 rectal cancer: a series of 15 ressectable cases

RACIONAL: A exenteração pélvica tem sido a melhor opção terapêutica radical para o tratamento dos tumores de reto T4. No entanto, essa operação ainda permanece com mortalidade significante e alta morbidade. OBJETIVO: Relatar série de 15 casos de exenteração pélvica para tumores de reto T4, analisando a morbidade, mortalidade e sobrevida dos pacientes. MÉTODOS: Foram estudados 15 pacientes com câncer de reto T4 no Serviço de Cirurgia Geral - Oncocirurgia do Hospital do Servidor Publico Estadual de São Paulo, SP, submetidos a exenteração pélvica no período de 1998 e 2006. Sete eram do sexo masculino enquanto oito eram do sexo feminino, com média de idade de 65 anos. Todos apresentavam sintomas incapacitantes. As operações foram: exenteração infra-elevadora (n = 6), exenteração supra-elevadora (n = 4), exenteração posterior (n = 3) e exenteração posterior com cistectomia e ureterectomia parciais (n = 2). RESULTADOS: A média de tempo cirúrgico foi de 403 minutos (280-485). A média de sangramento foi de 1620 mL (300-4800). A mortalidade pós-operatória foi de 6,66 por cento (n = 1). A morbidade pós-operatória foi de 53,3 por cento (n = 8). Os exames histológicos evidenciaram que todas as ressecções foram R0. Envolvimento linfonodal foi observado em quatro pacientes (26,66 por cento) sendo que todos faleceram em decorrência da neoplasia. A sobrevida global em cinco anos foi de 35,7 por cento. CONCLUSÃO: A exenteração pélvica ainda apresenta alta morbidade, no entanto permanece justificada, pois pode conferir maior controle do câncer de reto T4 em longo prazo.

BACKGROUND: Pelvic exenteration is the best therapeutic choice for treatment of T4 rectal cancer. Although, this operation still presents considerable mortality and high morbidity. AIM: To report on a series of 15 patients with a T4 rectal cancer at a general hospital and describe the outcomes (morbidity, mortality and long-term survival) following pelvic exenteration. METHODS: Complete follow-up data were available on 15 patients who underwent pelvic exenteration for T4 rectal cancer between 1998 and 2006. These subjects comprised seven men and eight women with a mean age of 65 years. All of them presented serious incapacitating complaints. The surgical procedures included: infraelevator exenteration (n = 6), supraelevator exenteration (n = 4), posterior exenteration (n = 3) and, posterior exenteration plus partial cystectomy and ureterectomy (n = 2). RESULTS: The mean duration of surgery was 403 minutes (280-485). The mean blood loss was 1620 mL (300-4.800). The postoperative mortality was 6,66 percent (n = 1). The overall rate morbidity was 53,3 percent (n = 8). The pathological examination showed that all resections were R0. Lymph node involvement was present in four patients (26,66 percent), and all of them died due to tumor recurrence. The overall 5-year survival rate was 35,7 percent. CONCLUSION: In spite of its aggressive nature and high morbidity, pelvic exenteration seems justified in rectal carcinoma when the disease extends to the urinary or genital tract. This procedure may offer long-term disease control.

Resultados del tratamiento quirúrgico del cáncer gástrico: Análisis de 423 casos / Surgical treatment of gastric cancer: results in 423 cases

Background: Gastric cancer is the second cause of cancer death worldwide and the first cause in Chile. Management of this pathology is controversial. Aim: To report the results on morbidity, mortality, and long-term survival rates of surgical treatment of gastric cancer, and compare them with those reported in the literature. Material and Methods: Follow up of 423 patients (aged 16 to 88 years, 271 males) operated for a gastric adenocarcinoma between 1996 and 2002. Patients were staged with the 5th edition of TNM staging system, and the 2nd edition in English of the Japanese Classification of Gastric Cancer. Morbidity was assessed using the classification of the Memorial Kettering Cancer Center group. Kapplan-Meier method was used to assay survival, and Log rank Test to compare long-term survivals. Results: Resectability of the lesions was 70.4 percent, and 88 percent of them corresponded to a curative-intended surgery. Seventy percent of patients were in stage TNM IIIA or higher at the moment of surgery. Mortality in curative intended operated patients was 4.2 percent, and morbidity was 33.7 percent. Overall five years survival rate was 33 percent: In the group with curative intended surgery it was 52 percent. Two years survival rate in the non intended curative group was 3.4 percent. Conclusions: The reported incidence of complications in our series is similar to that reported in the literature. Five year survival rates, morbidity and mortality were comparable to those reported abroad

Pancreatoduodenoctomía en el tratamiento de carcinoma del ámpula de Vater / Pancreatoduodenectomy in ampullary carcinoma

Objetivo: Analizar las características clínicas, estudios diagnósticos, hallazgos transoperatorios, morbimortalidad y evolución de una serie de pacientes con adenocarcinoma del ámpula de Vater. Diseño. Estudio retrospectivo. Lugar. Centro de tercer nivel de atención médica. Pacientes. 34 pacientes consecutivos tratados mediante cirugía radical entre 1960 y 1992. Resultados. Los hallazgos clínicos más frecuentes fueron: ictericia (91 por ciento), pérdida de peso (44 por ciento) y vesícula palpable (42 por ciento. Se practicó pancreatoduodenectomía a 33 enfermos (97 por ciento) y pancreatectomía total a uno (3 por ciento). La mortalidad operatoria fue del 15 por ciento. La supervivencia al año, 5, 10 y 14 años fueron 67 por ciento, 36 por ciento, 25 por ciento y 17 por ciento, respectivamente. Catorce pacientes fallecieron por recidiva tumoral a más de cinco años de la intervención. Conclusiones. La resección quirúrgica radical del adenocarcinoma de ámpula de Vater permite sobrevidas prolongadas